Codice QR

Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Abstract Background This phase II clinical trial evaluated the R2-GemOx-PD1i regimen, a combination of penpulimab (a modified PD1 inhibitor) with lenalidomide and rituximab, gemcitabine, and oxaliplatin, in treating refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). Methods Patients...

Descrizione completa

Salvato in:
Autori principali: Jin-Hua Liang, Tong-Yao Xing, Wei-Ying Gu, Hua Yin, Qing-Shu Zeng, Kai-Xin Du, Luthuli Sibusiso, Jia-Zhu Wu, Yue Li, Fei Wang, Rui Gao, Jian-Yong Li, Hao-Rui Shen, Li Wang, Wei Xu
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2026-02-01
Serie:BMC Medicine
Soggetti:
DLBCL
Penpulimab
Lenalidomide
R-GemOx
Efficacy
Relapsed
Accesso online:https://doi.org/10.1186/s12916-026-04679-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi